Literature DB >> 23180007

Immunity and hepatitis C: a review.

Rebecca R Terilli1, Andrea L Cox.   

Abstract

Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatocellular carcinoma worldwide. Due to shared transmission routes, the prevalence of HCV is especially high among individuals infected with HIV. HIV uninfected individuals spontaneously clear HCV approximately 30 % of the time, while the rate of control in HIV infected individuals who subsequently acquire HCV is substantially lower. In addition, complications of HCV are more frequent in those with HIV infection, making liver disease the leading cause of non-AIDS-related death in HIV infected individuals. This review summarizes recent advances in understanding the role of the innate and adaptive immune responses to HCV in those with and without HIV. Further defining the interaction between hepatitis C and the host immune system will potentially reveal insights into HCV pathogenesis and the host's ability to prevent persistent infection, as well as direct the development of vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23180007      PMCID: PMC3567217          DOI: 10.1007/s11904-012-0146-4

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  79 in total

1.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

2.  Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up.

Authors:  J M Christie; C J Healey; J Watson; V S Wong; M Duddridge; N Snowden; W M Rosenberg; K A Fleming; H Chapel; R W Chapman
Journal:  Clin Exp Immunol       Date:  1997-10       Impact factor: 4.330

3.  Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection.

Authors:  S Auffermann-Gretzinger; E B Keeffe; S Levy
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

4.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

5.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

6.  HCV persistence and immune evasion in the absence of memory T cell help.

Authors:  Arash Grakoui; Naglaa H Shoukry; David J Woollard; Jin-Hwan Han; Holly L Hanson; John Ghrayeb; Krishna K Murthy; Charles M Rice; Christopher M Walker
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

7.  Neutralizing antibody response during acute and chronic hepatitis C virus infection.

Authors:  C Logvinoff; M E Major; D Oldach; S Heyward; A Talal; P Balfe; S M Feinstone; H Alter; C M Rice; J A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

Review 8.  Innate immune responses in hepatitis C virus infection.

Authors:  Kui Li; Stanley M Lemon
Journal:  Semin Immunopathol       Date:  2012-08-07       Impact factor: 9.623

9.  Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus.

Authors:  Anne Fournillier; Delphine Freida; Thierry Defrance; Philippe Merle; Christian Trépo; Geneviève Inchauspé
Journal:  J Med Virol       Date:  2004-04       Impact factor: 2.327

10.  Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  13 in total

1.  Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.

Authors:  Abolghasem Asadi-Saghandi; Ali Shams; Gilda Eslami; Seyed Ali Mirghanizadeh; Ebrahim Eskandari-Nasab
Journal:  Virusdisease       Date:  2016-09-28

2.  Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.

Authors:  J Ampuero; J A del Campo; L Rojas; R J García-Lozano; M Buti; R Solá; X Forns; R Moreno-Otero; R Andrade; M Diago; J Salmerón; L Rodrigo; J A Pons; J M Navarro; J L Calleja; J García-Samaniego; M García-Valdecasas; Á Rojas; R Millán; M F González-Escribano; M Romero-Gómez
Journal:  Genes Immun       Date:  2015-04-30       Impact factor: 2.676

Review 3.  Hepatitis C virus infection in the human immunodeficiency virus infected patient.

Authors:  Louise Nygaard Clausen; Lene Fogt Lundbo; Thomas Benfield
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

4.  Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Authors:  Brian Latimer; Roberta Toporovski; Jian Yan; Panyupa Pankhong; Matthew P Morrow; Amir S Khan; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Authors:  Joseph M Cicchese; Stephanie Evans; Caitlin Hult; Louis R Joslyn; Timothy Wessler; Jess A Millar; Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; Denise E Kirschner
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

6.  Genetic disruption of CD8+ Treg activity enhances the immune response to viral infection.

Authors:  Tobias A W Holderried; Philipp A Lang; Hye-Jung Kim; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

Review 7.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.

Authors:  Alexei Zelenev; Jianghong Li; Alyona Mazhnaya; Sanjay Basu; Frederick L Altice
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071

Review 9.  Hepatitis C Virus Infection and Vaccine Development.

Authors:  Xuan Guo; Jin-Yi Zhong; Jun-Wen Li
Journal:  J Clin Exp Hepatol       Date:  2018-02-16

10.  Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea.

Authors:  Patrick Ying-Kit Yue; Yi-Yi Wong; Kay Yuen-Ki Wong; Yeuk-Ki Tsoi; Kelvin Sze-Yin Leung
Journal:  Chin Med       Date:  2013-11-01       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.